<DOC>
	<DOCNO>NCT00087256</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development cancer . It yet know whether celecoxib effective prevent polyps patient colon cancer . PURPOSE : Randomized phase III trial study effectiveness celecoxib prevent development polyp patient undergone surgery stage I colon cancer .</brief_summary>
	<brief_title>Celecoxib Preventing Polyps Patients Who Have Undergone Surgery Stage I Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare celecoxib vs placebo , term decrease incidence adenomatous polyp colon rectum , patient resect stage I adenocarcinoma colon . Secondary - Compare disease-free survival patient treat regimen . - Compare effect regimens self-reported symptom health-related quality life patient . - Compare quality life patient treat regimen . - Compare benefit celecoxib patient primary tumor polyps express cyclo-oxygenase-2 ( COX-2 ) express COX-2 . - Compare expression signal target serine/threonine AKT , extracellular signal-regulated kinase 2 ( ERK2 ) , endoplasmic reticulum Ca+2- ATPases index tumor polyp . - Determine toxicity safety celecoxib patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord gender , tumor stage ( T1 v T2 ) , age ( ≤ 49 v 50 59 v ≥ 60 year ) , current aspirin use ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral celecoxib twice daily 3 year . - Arm II : Patients receive oral placebo twice daily 3 year . In arm , treatment continue absence unacceptable toxicity diagnosis invasive colon cancer , carcinoma situ colon rectum , non-colon primary cancer . Quality life assess baseline 6 , 12 , 24 , 36 , 42 month . Patients follow 6 month 2 year . PROJECTED ACCRUAL : A total 1,200 patient ( 600 per treatment arm ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon Stage I disease Distal border tumor ≥ 12 cm anal verge Tumor completely resect within past 90 day Must undergone preoperative postoperative colonoscopy cecum ( small bowel anastomosis ) within past 90 day All observed polyp must remove Patients history suggestive hereditary nonpolyposis colorectal cancer ( HNPCC ) must normal microsatellite instability status immunohistochemistry polymerase chain reaction Patients family history colon cancer diagnose HNPCC eligible No prior familial adenomatous polyposis No prior invasive cancer carcinoma situ colon rectum No clinical radiologic evidence metastatic disease PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy At least 10 year Hematopoietic Complete blood count normal Platelet count normal Hepatic Aspartate aminotransferase ( AST ) normal Bilirubin normal Alkaline phosphatase normal Renal Creatinine normal Cardiovascular No active ischemic heart disease No New York Heart Association class III IV heart disease No myocardial infarction within past 6 month No symptomatic arrhythmia No symptomatic peripheral vascular disease carotid disease would preclude study participation Pulmonary No aspirinsensitive asthma Gastrointestinal No history inflammatory bowel disease No history upper gastrointestinal bleeding No history duodenal gastric ulcer Other No know hypersensitivity COX2 inhibitor , NSAIDs , aspirin , sulfonamides No noncolorectal malignancy within past 5 year except carcinoma situ cervix , melanoma situ , basal cell squamous cell skin cancer No disease would preclude study participation No psychiatric disorder , include history clinical depression addictive disorder , would preclude give informed consent longterm compliance No rheumatologic skeletal disorder require chronic NSAIDs steroid therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics Other No concurrent investigational agent colon cancer No concurrent chronic use cyclooxygenase2 ( COX2 ) inhibitor , nonsteroidal antiinflammatory drug ( NSAIDs ) , salicylates ( e.g. , aspirin ) Chronic use define use average 3 day per month Concurrent NSAIDs allow 10 consecutive day temporary relief due inflammatory syndrome , injury , postoperative pain Cardioprotective dose aspirin ( ≤ 81 mg/day 325 mg every day ) allow No concurrent fluconazole lithium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage I colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
</DOC>